![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 13, 2022 7:17:13 PM
Another point you'll never talk about: Powers gave up her interest in Cognate in a management-led buyout financed by some 3rd party(ies). I don't think we know the buyout terms but we do know that a few years later, Cognate was purchased by CRL. IIRC the purchase price was $800M. From where I'm sitting it appears certain that Powers lost the opportunity for far greater financial gain if she had just held her interest in Cognate another year or two than she realized in selling when she did, and I'm sure that she did so to get out of the conflict of interest, which admittedly was not a great situation WRT corporate governance.
It's certainly a fact that she benefitted from owning Cognate while they grew their business (how largely Cognate's business success depended on NWBO alone I would not know but obviously they built a very successful business besides with NWBO alone) on the base of supplying NWBO for their trials and other activity. However, it's also certain that she gave up the huge additional profit that was realized when Cognate was sold on to CRL. Since you want to focus on how much Cognate profited from their relationship with NWBO while building a very successful business including gaining valuable contracts with other companies, I'm sure you overlook the fact that she gave up several hundred millions of larger profit that she could have had if she had held onto ownership of Cognate another couple of years. You obviously ignore that fact because you want to paint her as a terrible villain but I think you distort the true picture.
When it comes to NWBO retaining the services of Advent Bioloservices I'm sure that the prime reason that NWBO ex-Powers went along with that in spite of repeating the financial conflict of interest due to Power's personal stake in Advent, was the fact that Mike Scott is a genius and super experienced in cellular technology, with 30 years experience and a professorship, and BTW I believe he already had a team including other cellular science PhDs. Do you really think it would have been easy for NWBO to assemble a similarly qualified team of experts in the technologies so key to their success? I'm sure it would not, especially guys like Mike Scott are few and far between! This is Scott's bio:
Mike brings a wealth of experience to Advent Bioservices, having held several senior clinical and scientific positions within the NHS and in academia. He has spent 30 years in the field of cellular therapy and has co-authored more than 90 papers. Mike has Masters’ degrees in haematology and immunology and his PhD was in the area of stem cell biology. He is a Fellow of the Royal Society of Biology, a Fellow of the Royal College of Pathologists and holds a visiting Professorship at Anglia Ruskin University.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM